|
|
Treatment Studies
Effect of Gamma-Secretase Inhibition on the
Progression
of Alzheimer’s Disease (AD)
This is a Phase III research study of the effect of LY450139,
an oral compound, on the progression of Alzheimer’s
disease. Men and women age 55 and older with mild
to moderate AD may be eligible to participate. For more
information, please contact Lynda Mules at 212-305-2077.
GLAD: The Gammaglobulin Liquid for Alzheimer’s
Disease (AD) Trial
This is a Phase III research study of intravenous immune
globulin (“IGIV”) in mild to moderate AD. Men and
women who are 50 to 85 years old with mild to moderate
AD may be eligible to participate. For more information,
please contact Ruth Tejeda at 212-305-7661.
Study of Bapineuzumab (AAB-001) Administered
by IV
Infusion in Alzheimer’s Disease (ICARA)
This is a Phase III research study of bapineuzumab
administered by IV infusion which researchers hope will
attach to the amyloid protein in the brain and help the
body to remove it. Individuals diagnosed with mild to
moderate probable AD who are 50 to 88 years old may
be eligible to participate. For more information, please contact
Evelyn Dominguez at 212-305-2371.
Study of Bapineuzumab (AAB-001) Administered
Subcutaneously
in Alzheimer’s Disease (AD)
This is a Phase II research study of bapineuzumab
administered by injection. Men and women with mild
to moderate AD who are 50 to 89 years old may be
eligible to participate. For more information, please contact
Evelyn Dominguez at 212-305-2371.
Study of CAD106 in Mild Alzheimer’s Disease (AD)
This is a 52-week Phase II research study to evaluate
the safety and tolerability of CAD106 administered
by injection, which researchers hope may prevent the
formation of plaques in the brain. Men and women with
mild AD who are 40 to 85 years old may be eligible to
participate. For more information, please contact Lynda Mules at
212-305-2077.
Study of ACC-001 Administered Subcutaneously in
Alzheimer’s Disease (AD)
This is a Phase IIa research study of ACC-001
administered by injection. Men and women with mild
to moderate AD who are 50 to 85 years old may be
eligible to participate. For more information, please contact
Evelyn Dominguez at 212-305-2371.
Study of Memantine in Frontotemporal Dementia
This is a Phase IV research study to determine if
memantine is effective in slowing the rate of behavioral
decline in frontotemporal dementia. English-speaking
men and women who are 40 to 80 years old and who
have been diagnosed with frontotemporal dementia
(FTD) or semantic dementia (SD) may be eligible. For
further information, please contact Lynda Mules at 212-305-2077.
Metformin in Amnestic Mild Cognitive Impairment
(MCI)
This is a 12-month research study of metformin, a
medication effective in the prevention and treatment
of diabetes. We are testing metformin in people with
MCI. We are seeking people over the age of 55 who are
overweight or obese and have memory complaints. For
more information, please contact Dr. José Luchsinger at 212-305-4730.
Antipsychotic Medication Treatment of Psychosis and
Behavioral Dyscontrol in Alzheimer’s Disease (AD)
This research study uses risperidone (an FDA-approved
antipsychotic medication) to treat people with AD who
suffer from hallucinations, delusions, agitation, and/or
aggression. Treatment continues over 48 weeks. Each
participant must have a caregiver to assist with adherence
to treatment and provide information. For further information,
please contact Karine Cunqueiro at 212-543-6132.
Antidepressant Treatment Studies for Combined
Depression
and Memory Complaints
We are conducting medication treatment research studies
for individuals age 50+ with both depression and mild
memory and/or concentration difficulties. The studies
offer neuropsychological testing for memory and
psychiatric evaluation of mood. Treatment is provided
for eligible individuals at no cost for at least 6 months. For
more information, please contact Amma Baker at 212-543-5067.
Other Studies
Brain Imaging Study Measuring Changes in Cerebral
Blood Flow and Cognition with Age
We are seeking healthy individuals and people with
memory complaints or with Alzheimer’s disease, age 55
to 85, to participate in a research study using Arterial Spin
Labeling (ASL), a technique that uses MRI to measure
cerebral blood flow in the brain. The study consists of
three visits and includes an MRI and memory testing,
and participants will be compensated. Please contact Brittany
Holmes at 212-305-7846 for more information.
Genetic Linkage Study
We are seeking families of all nationalities and backgrounds
for a study that seeks to identify genes that may increase
the risk for developing Alzheimer’s disease (AD). If your
family has at least two living siblings diagnosed with AD
who are 60 years old or older, please call Jennifer Williamson
at 212-305-4655.
Predictors Study
This research study is for people who are 55 to 90 years
old who have been diagnosed with Alzheimer’s disease
and/or Dementia with Lewy Bodies. Participation
includes initial medical evaluation and testing to assess
memory and cognitive functions. This longitudinal study
requires bi-annual visits which include memory testing
and answering questions about daily activities. For more
information, please call 212-305-1987.
Memory Problems II: Course and Predictors of
Outcome
This research study for people with and without memory
complaints who are 55 to 90 years old includes medical
evaluation by physicians who specialize in memory
disorders, and testing to assess memory and intellectual
functions. Visits and monitoring will take place annually
for 7 years. At the initial visit only, an MRI scan, two
PET scans and a lumbar puncture will be performed.
Participants will receive reimbursement. For more information,
please call 212-543-5025.
African American Genetics Study and Health and
Cognition Study among African American Women
The African American Genetics Study, for people over the
age of 60, looks at genetic risk factors for Alzheimer’s
disease among African Americans. The Health and
Cognition Study among African American Women investigates
issues of aging, cardiovascular health and cognition among
African American women 40 years or older. Both studies
involve an interview to include memory and thinking
tests, questions about your health and experiences, and
a blood draw. For further information, please call Raquel Cabo at
212-305-1893.
Brain Donation Program
“Give the Gift of Knowledge”
Brain donation allows valuable information to be
obtained regarding normal aging and diseases that affect
memory. To learn more about this program for yourself or a family
member, please call Arlene Lawton, RN at 212-305-9086.
Lucy G. Moses Center for Memory and Behavioral
Disorders
Changes in memory and thinking abilities can occur from
a variety of conditions, not just Alzheimer’s disease. Taub
Institute specialists offer a thorough multidisciplinary
evaluation of memory and thinking difficulties at two
locations: The Neurological Institute, 710 West 168th Street, New
York; and Columbia Presbyterian Eastside, 16 East 60th Street, New
York. For appointments, call 212-305-6939.
|
Previous
